Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

The nonsurgical treatment of cholangiocarcinoma has seen major changes within the last few years. A multidisciplinary approach is the cornerstone in planning optimal treatment, but despite several examinations the diagnosis is often based on a certain probability, and histopathological confirmation is not always possible. Chemotherapy is effective and the combination of cisplatin and gemcitabine is considered a standard treatment of inoperable cholangiocarcinoma. Biological targeted treatment to date has minor effect when given as monotherapy, but some of the drugs hold promise as an adjunct to chemotherapy. It should, however, be noted that most of the trials are based on few patients, and thus far the literature does not allow for a conclusion as to the role of biological treatment on cholangiocarcinoma. This situation calls for well-designed randomized trials, and international cooperation as well as marker-driven therapy seems mandatory for treatment progress within a reasonable time.
OriginalsprogEngelsk
TidsskriftExpert Review of Anticancer Therapy
Vol/bind11
Udgave nummer4
Sider (fra-til)589-600
ISSN1473-7140
DOI
StatusUdgivet - 2011

Fingeraftryk

gemcitabine
Cisplatin
Pharmaceutical Preparations

Citer dette

@article{e31384fbf0d04104a8e6ff49f0232a63,
title = "Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma",
abstract = "The nonsurgical treatment of cholangiocarcinoma has seen major changes within the last few years. A multidisciplinary approach is the cornerstone in planning optimal treatment, but despite several examinations the diagnosis is often based on a certain probability, and histopathological confirmation is not always possible. Chemotherapy is effective and the combination of cisplatin and gemcitabine is considered a standard treatment of inoperable cholangiocarcinoma. Biological targeted treatment to date has minor effect when given as monotherapy, but some of the drugs hold promise as an adjunct to chemotherapy. It should, however, be noted that most of the trials are based on few patients, and thus far the literature does not allow for a conclusion as to the role of biological treatment on cholangiocarcinoma. This situation calls for well-designed randomized trials, and international cooperation as well as marker-driven therapy seems mandatory for treatment progress within a reasonable time.",
keywords = "Antineoplastic Agents, Bile Duct Neoplasms, Bile Ducts, Intrahepatic, Biological Agents, Cholangiocarcinoma, Humans, Molecular Targeted Therapy",
author = "Jensen, {Lars Henrik} and Anders Jakobsen",
year = "2011",
doi = "10.1586/era.11.17",
language = "English",
volume = "11",
pages = "589--600",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Taylor & Francis",
number = "4",

}

Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. / Jensen, Lars Henrik; Jakobsen, Anders.

I: Expert Review of Anticancer Therapy, Bind 11, Nr. 4, 2011, s. 589-600.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma

AU - Jensen, Lars Henrik

AU - Jakobsen, Anders

PY - 2011

Y1 - 2011

N2 - The nonsurgical treatment of cholangiocarcinoma has seen major changes within the last few years. A multidisciplinary approach is the cornerstone in planning optimal treatment, but despite several examinations the diagnosis is often based on a certain probability, and histopathological confirmation is not always possible. Chemotherapy is effective and the combination of cisplatin and gemcitabine is considered a standard treatment of inoperable cholangiocarcinoma. Biological targeted treatment to date has minor effect when given as monotherapy, but some of the drugs hold promise as an adjunct to chemotherapy. It should, however, be noted that most of the trials are based on few patients, and thus far the literature does not allow for a conclusion as to the role of biological treatment on cholangiocarcinoma. This situation calls for well-designed randomized trials, and international cooperation as well as marker-driven therapy seems mandatory for treatment progress within a reasonable time.

AB - The nonsurgical treatment of cholangiocarcinoma has seen major changes within the last few years. A multidisciplinary approach is the cornerstone in planning optimal treatment, but despite several examinations the diagnosis is often based on a certain probability, and histopathological confirmation is not always possible. Chemotherapy is effective and the combination of cisplatin and gemcitabine is considered a standard treatment of inoperable cholangiocarcinoma. Biological targeted treatment to date has minor effect when given as monotherapy, but some of the drugs hold promise as an adjunct to chemotherapy. It should, however, be noted that most of the trials are based on few patients, and thus far the literature does not allow for a conclusion as to the role of biological treatment on cholangiocarcinoma. This situation calls for well-designed randomized trials, and international cooperation as well as marker-driven therapy seems mandatory for treatment progress within a reasonable time.

KW - Antineoplastic Agents

KW - Bile Duct Neoplasms

KW - Bile Ducts, Intrahepatic

KW - Biological Agents

KW - Cholangiocarcinoma

KW - Humans

KW - Molecular Targeted Therapy

U2 - 10.1586/era.11.17

DO - 10.1586/era.11.17

M3 - Journal article

C2 - 21504326

VL - 11

SP - 589

EP - 600

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 4

ER -